2024
Comparison of Outcomes of Hematopoietic Cell Transplantation (HCT) for Asymptomatic Patients with Sickle Cell Disease (SCD) and That of Propensity Matched Symptomatic Patients Undergoing HCT
Katoch D, Nallagatla V, Liang J, Deng Y, Krishnamurti L. Comparison of Outcomes of Hematopoietic Cell Transplantation (HCT) for Asymptomatic Patients with Sickle Cell Disease (SCD) and That of Propensity Matched Symptomatic Patients Undergoing HCT. Transplantation And Cellular Therapy 2024, 30: s65. DOI: 10.1016/j.jtct.2023.12.103.Peer-Reviewed Original ResearchHematopoietic cell transplantationOutcomes of hematopoietic cell transplantationSickle cell diseaseSymptomatic SCD patientsAsymptomatic patientsDonor typeSymptomatic patientsPost-HCTSCD patientsHematopoietic cell transplantation comorbidity indexPost-transplant lymphoproliferative disorderMedian follow-up periodComplication of sickle cell diseaseIncidence of aGVHDReduced intensity conditioningSickle cell disease patientsFollow-up periodPropensity-matched modelStandardized mean differenceSecondary malignanciesLymphoproliferative disordersCell transplantationGraft survivalPatient ageAssociated with group classification
2023
Abatacept-Prophylaxis Based Haploidentical Transplantation May Allow Sustained Engraftment and Offset Gvhd in Non-Malignant Disorders
Ngwube A, Shah N, Schulz G, Krishnamurti L, Shenoy S. Abatacept-Prophylaxis Based Haploidentical Transplantation May Allow Sustained Engraftment and Offset Gvhd in Non-Malignant Disorders. Blood 2023, 142: 4901. DOI: 10.1182/blood-2023-191145.Peer-Reviewed Original ResearchNon-malignant disordersPost-transplant cyclophosphamideSickle cell diseaseGVHD prophylaxisHematopoietic transplantationEvaluable patientsHaploidentical transplantationImmune suppressionBone marrowFirst year post-HCTGrade 1 acute GVHDChronic GVHD riskChronic skin GVHDGVHD-free survivalPost-transplant lymphoproliferationsRadiation-containing regimensYear post-HCTPhase 2 trialReduced intensity conditioningSerious infectious complicationsSystemic immune suppressionT-cell chimerismAllogeneic hematopoietic transplantationPrimary outcome measureStem cell boost